[{"orgOrder":0,"company":"SK Chemicals","sponsor":"AriBio","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"CREB pathway","graph1":"Neurology","graph2":"Phase III","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Chemicals \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"SK Chemicals \/ SK Chemicals"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Standigm","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"SK Chemicals \/ SK Chemicals","highestDevelopmentStatusID":"4","companyTruncated":"SK Chemicals \/ SK Chemicals"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"SARS-CoV-2 Surface Spike Protein","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SK Chemicals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Chemicals \/ Not Applicable"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"AS03","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Chemicals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Chemicals \/ Not Applicable"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Tiumbio","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Merigolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SK Chemicals \/ SK Chemicals","highestDevelopmentStatusID":"8","companyTruncated":"SK Chemicals \/ SK Chemicals"}]

Find Clinical Drug Pipeline Developments & Deals by SK Chemicals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.

                          Brand Name : TU2670

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 29, 2023

                          Lead Product(s) : Merigolix

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Recipient : Tiumbio

                          Deal Size : Undisclosed

                          Deal Type : Private Placement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.

                          Brand Name : SKYCovion

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          May 26, 2023

                          Lead Product(s) : Recombinant Adjuvanted Covid-19 Vaccine,AS03

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Skycovion,a vaccine for protecting against Covid-19 has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.

                          Brand Name : Skycovion

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          August 20, 2022

                          Lead Product(s) : SARS-CoV-2 Surface Spike Protein,Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The compound in the patent was discovered by Standigm Insight™. In a mouse model, it showed comparable or better improvements in its rheumatoid arthritis disease activity score than reference drugs such as methotrexate and hydroxychloroquine.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          January 07, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Recipient : Standigm

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AriBio completed enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.

                          Brand Name : AR1001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 17, 2020

                          Lead Product(s) : Methylbenzylamine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Recipient : AriBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank